AMENDMENT TO INTERIM CHIEF EXECUTIVE OFFICER AGREEMENTInterim Chief Executive Officer Agreement • September 18th, 2024 • Akari Therapeutics PLC • Pharmaceutical preparations
This Amendment (this “Amendment”) to the Interim Chief Executive Officer Agreement (the “Interim CEO Agreement”), effective May 1, 2024, between Samir R. Patel, M.D. (“Interim CEO”) and Akari Therapeutics, Plc (the “Company”) is effective as of July 1, 2024. All capitalized terms used herein but not otherwise defined shall have the meaning given to such terms in the Interim CEO Agreement.
